New psoriasis drug candidate begins first human tests
NCT ID NCT07078695
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-stage study tests a single dose of SHR-1139 in 24 healthy adults to check its safety, how the body processes it, and whether it triggers an immune response. It is a first step toward a possible treatment for psoriasis. No direct benefit is expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linear
Perth, Western Australia, Australia
Conditions
Explore the condition pages connected to this study.